Phase 3 Study Now Enrolling for MDS MEDALIST is an international, pivotal clinical trial for patients who have myelodysplastic syndrome (MDS). MEDALIST will determine whether an investigational drug called luspatercept* can help * reduce the number of red blood cell transfusions * improve the symptoms of anemia associated with MDS IF YOUR PATIENTS HAVE MDS of very low-, low-, or intermediate risk and require blood transfusions, they may be eligible for the MEDALIST Trial. Please consider discussing with your eligible patients whether the MEDALIST Trial is an option for them. Learn more about MEDALIST at www.clinicaltrials.gov by searching for NCT02631070 Visit the CELGENE booth at the 58th ASH Annual Meeting & Exposition in San Diego. in partnership with Acceleron Pharma ©2016 Celgene Corporation All rights reserved. 9/16 Version 1 Celgene Medalist Blood bag ad_HCP_P1_JG_9-30-16.indd 1 *The safety and efficacy of luspatercept has not been established. There is no guarantee that luspatercept will become commercially available. Celgene Medalist HCP Ad_V1.0_26-Sept-16 9/30/16 9:35 AM